Global Leading Market Research Publisher QYResearch announces the release of its latest report “Hepatitis Virus Blood Test – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Hepatitis Virus Blood Test market, including market size, share, demand, industry development status, and forecasts for the next few years.
Market Analysis: A High-Growth Trajectory in Infectious Disease Diagnostics
The global hepatitis virus blood test market is positioned for robust expansion over the forecast period, driven by the World Health Organization’s global viral hepatitis elimination goals, increasing prevalence of chronic hepatitis B and C infections, expanding screening programs in high-burden regions, and growing adoption of rapid diagnostic tests for point-of-care use. According to QYResearch’s latest market intelligence, the market was valued at US$ 1,261 million in 2025 and is projected to reach US$ 1,948 million by 2032, reflecting a strong compound annual growth rate (CAGR) of 6.5%.
For clinicians, public health officials, and diagnostic laboratory directors, the core challenge in viral hepatitis management has intensified: accurately detecting current or past hepatitis virus infections, assessing disease stage, monitoring treatment response, and determining immunity status—all critical for achieving global elimination targets. Hepatitis viruses (A, B, C, D, and E) affect hundreds of millions worldwide, with chronic hepatitis B and C leading causes of liver cirrhosis and hepatocellular carcinoma. Hepatitis virus blood tests address this critical need by providing blood tests designed to detect the presence of hepatitis viruses or markers of infection—including antibodies, antigens, or viral genetic material—in the bloodstream. These tests enable diagnosis of current or past hepatitis virus infections, assessment of disease stage, monitoring of treatment response, and determination of immunity status, serving as essential tools in the global effort to eliminate viral hepatitis as a public health threat.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6091268/hepatitis-virus-blood-test
Key Industry Characteristics Shaping Market Dynamics
1. Global Public Health Priority: WHO Viral Hepatitis Elimination Goals
The hepatitis virus blood test market is fundamentally driven by global public health initiatives:
WHO elimination targets: Goal to eliminate viral hepatitis as a public health threat by 2030 (90% diagnosed, 80% treated)
Screening expansion: National screening programs in high-burden countries (China, India, Nigeria, and others)
Birth dose vaccination: Hepatitis B birth dose vaccination programs requiring screening for maternal infection
Blood safety: Donor screening for transfusion-transmitted hepatitis viruses
Monitoring requirements: Treatment monitoring for chronic hepatitis B and C patients
2. Test Type Segmentation Across Hepatitis Viruses
The hepatitis virus blood test market encompasses tests for multiple viral types:
Hepatitis A virus (HAV) Tests: Serological detection of anti-HAV IgM (acute infection) and anti-HAV IgG (past infection/immunity)
Hepatitis B virus (HBV) Tests: Largest segment, including HBsAg (current infection), anti-HBc (past infection), anti-HBs (immunity), HBeAg (replication), and HBV DNA (viral load)
Hepatitis C virus (HCV) Tests: Anti-HCV antibody screening and HCV RNA confirmation and viral load monitoring
Other: Hepatitis D and E virus tests for specialized applications
3. Application Segmentation Across Healthcare Settings
The hepatitis virus blood test market serves diverse clinical and public health settings:
Hospital: Largest segment, encompassing inpatient and outpatient testing, specialty hepatology clinics, and pre-surgical screening
Clinic: Primary care and community health center testing for screening programs
Home: Rapid diagnostic tests and self-testing kits for point-of-care and decentralized testing
4. Competitive Landscape and Market Concentration
The hepatitis virus blood test market features a concentrated competitive landscape:
Global Diagnostic Leaders:
Roche Diagnostics: Comprehensive hepatitis testing portfolio including molecular and serological platforms
Abbott Rapid Diagnostics: Rapid diagnostic tests and laboratory platforms
Siemens Healthineers, Becton, Dickinson and Company: Laboratory diagnostics and point-of-care solutions
Bio-Rad Laboratories: Immunoassay and molecular testing
Pharmaceutical and Vaccine Manufacturers:
GSK, Merck, Sanofi: Hepatitis vaccine manufacturers with diagnostic presence
Sinovac, Zhejiang Pukang, Changchun Institute of Biological, KM Biologics, IMBCA, ChangSheng, Convac: Asia-Pacific vaccine and diagnostic manufacturers
Rapid Test Specialists:
Wondfo, Wantai Bio: China-based rapid diagnostic test manufacturers with global distribution
5. Technology Platforms and Testing Paradigms
The hepatitis virus blood test market utilizes multiple technology platforms:
Serological immunoassays: ELISA, chemiluminescence, and rapid lateral flow tests for antibody and antigen detection
Molecular diagnostics: PCR and nucleic acid amplification tests for viral DNA/RNA detection and quantification
Point-of-care tests: Rapid, instrument-free tests for decentralized and home-based screening
Automated platforms: High-throughput laboratory systems for screening programs
Exclusive Industry Perspective: Laboratory-Based vs. Point-of-Care Testing
A critical distinction within the hepatitis virus blood test market lies between laboratory-based testing and point-of-care/rapid testing:
Laboratory-Based Testing: Characterized by:
High throughput: Automated platforms for population screening programs
Comprehensive results: Full serological panel and viral load quantification
Regulatory requirements: Centralized laboratory infrastructure and trained personnel
Higher cost: Instrumentation and per-test costs
Applications: Blood donor screening, confirmatory testing, treatment monitoring
Point-of-Care/Rapid Testing: Characterized by:
Decentralized access: Testing in community clinics, pharmacies, and home settings
Rapid results: 15-30 minute turnaround for screening
Simplified operation: Minimal equipment and training requirements
Lower cost per test: Affordable for screening programs
Applications: Community screening, self-testing, resource-limited settings
This divergence influences market strategies, with laboratory-based testing dominating confirmatory and monitoring applications, while point-of-care testing drives screening expansion and access.
Recent Industry Developments and Market Implications
Recent developments have reinforced the market’s growth trajectory:
WHO elimination strategy: Accelerated global efforts to diagnose 90% of chronic hepatitis B and C cases by 2030
China hepatitis B screening: National programs for hepatitis B screening and maternal-infant transmission prevention
HCV elimination programs: National hepatitis C elimination programs in Egypt, Georgia, and other high-burden countries
Self-testing adoption: WHO prequalification of hepatitis C self-tests expanding access
Blood safety programs: Donor screening expansion in emerging markets
Market Challenges and Strategic Considerations
Despite strong growth, the hepatitis virus blood test market faces significant challenges:
Diagnosis gaps: Large undiagnosed populations, particularly for chronic hepatitis B and C
Access barriers: Limited testing infrastructure in resource-limited settings
Confirmatory testing: Need for molecular confirmation following positive serological screens
Cost constraints: Pricing pressures in public health screening programs
Competing priorities: Pandemic-related disruptions to routine screening programs
Strategic Implications for Industry Decision-Makers
For diagnostic executives, public health leaders, and investors, the hepatitis virus blood test market presents clear strategic considerations:
Portfolio breadth: Offer comprehensive hepatitis testing across serological and molecular platforms
Decentralized solutions: Develop point-of-care and self-testing solutions for screening expansion
Integrated diagnostics: Combine screening, confirmatory, and monitoring capabilities
Global partnerships: Collaborate with public health organizations for elimination programs
Emerging markets: Focus on high-burden regions with expanding screening programs
Conclusion
As the global public health community accelerates efforts to eliminate viral hepatitis by 2030, hepatitis virus blood tests remain essential for diagnosis, screening, treatment monitoring, and immunity assessment across healthcare settings. With a projected market value of US$ 1.95 billion by 2032 and a 6.5% CAGR, the industry offers substantial growth opportunities for established diagnostic leaders and rapid test specialists. The strategic imperative is clear: deliver accessible, accurate testing solutions; support global elimination programs; and enable early diagnosis and treatment of viral hepatitis worldwide.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
